Check Up: Why Goldman Sachs won't change its ratings on 3 AS

Check Up: Why Goldman Sachs won't change its ratings on 3 ASX stocks despite Ozempic-driven sell-off

Check Up: Why Goldman Sachs won't change its ratings on 3 ASX stocks despite Ozempic-driven sell-off

theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Australia , United Kingdom , Denmark , New Zealand , Switzerland , Canada , Australian , Swiss , Danish , Advanz Pharma , Peter Mac , Novo Nordisk Ozempic , Byeddy Sunarto , Global Health , Chinese Society Of Colposcopy , Novo Nordisk , Peak Processing Solutions , Data Monitoring Committee , Precedence Research , Philips , Peter Maccallum Cancer Centre , Goldman Sachs , While Ozempic , Getty Images , Paykel Healthcare , Independent Data Monitoring Committee , Orphan Drug Designation , Dimerix Phase , European Economic Area , Biobeat Medical , Matrix Medical , Chinese Society , Cervical Pathology , Health Canada Licensed ,